Home › Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions

2013-03-09 18:50:00| Merck.com - Research & Development News

Dateline City:  SAN FRANCISCO SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers from the Clinical Trial Service Unit at Oxford University presented results from the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) during a late-breaking clinical trials session at the American College of Cardiology 62nd Annual Scientific Sessions (abstract 300-14). Language:  English Contact HTML:  MerckMedia:Pamela Eisele, 908-423-5042Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results american study college

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Atlantic Tropical Weather Outlook
30.09Eastern North Pacific Tropical Weather Outlook
30.09Miraclon joins Consortium for Waste Circularity
30.09Post Office minister 'horrified' at more IT faults
30.09PPGs SEM Products Business Launches Performance Abrasives Product Line
30.09Pulse demonstrates Monolox at Mark Andy Poland workshop
30.09EMT International names John Pecoraro regional sales manager
30.09IDENTCO chosen by watercraft provider for label durability
More »